LITS.US Lite Strategy, Inc.
- Market cap
- USD 25.3M
- P/E
- -
- P/B
- 0.44x
- ROE
- 113.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.
Is LITS.US undervalued?
Graham numberThe Graham number of Lite Strategy, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lite Strategy, Inc. fundamental analysis
No fundamental analysis for Lite Strategy, Inc. yet.
Lite Strategy, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lite Strategy, Inc.
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. It is also involved in holding Litecoin tokens as a primary reserve asset. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.
Full company profileLite Strategy, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Lite Strategy, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 23.2M | 1.62M | 4.92M | 28.9M | 34.8M | 40.7M | 48.8M | 65.3M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 18.2M | -1.76M | 652K | 26.2M | 33.4M | 40.7M | 48.8M | 65.3M | -368K | - | - |
| Operating Income | 2.38M | -28.6M | -46.2M | -24.5M | -60.4M | -75.5M | -36.8M | 14.5M | -17.5M | -12.3M | -9.51M |
| EBITDA | 2.47M | -28.5M | -46.2M | -24.4M | -41.0M | -75.2M | -36.4M | 25.8M | -17.1M | -12.3M | -9.51M |
| Net Income | 2.67M | -40.1M | -16.8M | -46.0M | -41.3M | -54.5M | -31.8M | 17.8M | -15.9M | -71.2M | 64.1M |
| EPS | 1.45 | -19 | -4.65 | -10 | -7.22 | -8.70 | -4.78 | 2.67 | -2.39 | -2.06 | 1.93 |
| Balance Sheet | |||||||||||
| Total Assets | 55.7M | 105M | 82.7M | 210M | 174M | 178M | 121M | 41.4M | 18.3M | 42.7M | 58.4M |
| Total Liabilities | 4.87M | 54.2M | 34.7M | 133M | 125M | 125M | 96.2M | 8.36M | 1.35M | 1.07M | 1.71M |
| Shareholders' Equity | 50.8M | 50.5M | 47.9M | 77.1M | 49.5M | 52.4M | 24.6M | 33.0M | 16.9M | 41.6M | 56.7M |
| Cash & Short-term Investments | 53.6M | 103M | 74.5M | 183M | 153M | 153M | 101M | 38.3M | 18.0M | 5.71M | 4.28M |
| Total Debt | - | - | - | - | 8.30M | 9.64M | 12.7M | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 3.49M | -21.0M | -29.4M | 34.3M | -32.0M | -48.7M | -52.5M | -50.5M | -20.8M | -9.12M | -8.70M |
| Capital Expenditure | 51.0K | 0.00 | 217K | 894K | 708K | 479K | 35.0K | 7.00K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | 3.44M | -21.0M | -29.6M | 33.4M | -32.7M | -49.2M | -52.5M | -50.5M | -20.8M | -9.12M | -8.70M |
| Ratios | |||||||||||
| ROE | 5.3% | -79.4% | -35.1% | -59.7% | -83.5% | -103.9% | -129.3% | 53.8% | -94.2% | -170.9% | 113.0% |
| ROA | 4.8% | -38.3% | -20.3% | -21.9% | -23.7% | -30.6% | -26.4% | 43.0% | -87.2% | -166.7% | 109.7% |
| Net Profit Margin | 11.5% | -2,470.3% | -342.2% | -159.2% | -118.7% | -133.8% | -65.2% | 27.2% | - | - | - |
| Debt to Equity | - | - | - | - | 0.17x | 0.18x | 0.52x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Lite Strategy, Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Nov 16, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | USD 11.7M | 1.75 | 65.6% |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:20 on Apr 17, 2023.
Who owns Lite Strategy, Inc.
- Insiders 1.46%
- Institutions 17.91%
- Public & others 80.63%
- Shares outstanding 29.9M
- Free float 27.7M
Top funds holding LITS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 660K | 2.21% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 164K | 0.55% | -0.38% | Sep 2026 |
| iShares Micro-Cap ETF | 100K | 0.34% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 54.5K | 0.18% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 49.7K | 0.17% | 0.00% | Sep 2026 |
| Nomura Healthcare Fund Class I | 30.0K | 0.10% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 17.9K | 0.06% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 13.4K | 0.04% | 0.00% | Aug 2026 |
| 1290 VT Micro Cap K | 7.35K | 0.02% | 0.00% | Sep 2026 |
| Guggenheim Active Allocation Fund | 66.00 | 0.00% | 0.00% | Aug 2026 |
Top institutions holding LITS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 1.02M | 3.42% | -2.05% | Jun 2026 |
| Renaissance Technologies Corp | 966K | 3.23% | -22.55% | Sep 2026 |
| RLH Capital LLC | 806K | 2.70% | 0.00% | Jun 2026 |
| Two Sigma Investments LLC | 557K | 1.86% | -9.35% | Jun 2026 |
| Geode Capital Management, LLC | 365K | 1.22% | -8.99% | Jun 2026 |
| Citadel Advisors Llc | 358K | 1.20% | -51.03% | Jun 2026 |
| BlackRock Inc | 276K | 0.92% | +74.70% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 233K | 0.78% | -30.14% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 195K | 0.65% | +0.72% | Jun 2026 |
| Jane Street Group LLC | 193K | 0.64% | +236.49% | Jun 2026 |
| State Street Corp | 115K | 0.38% | 0.00% | Jun 2026 |
| UBS Group AG | 91.1K | 0.31% | +77.49% | Jun 2026 |
| Northern Trust Corp | 75.5K | 0.25% | -5.90% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 71.4K | 0.24% | +0.07% | Jun 2026 |
| XTX Topco Ltd | 68.2K | 0.23% | -49.89% | Jun 2026 |
| ADAR1 Capital Management LLC | 67.3K | 0.23% | 0.00% | Jun 2026 |
| GSA Capital Partners LLP | 61.9K | 0.21% | 0.00% | Jun 2026 |
| Delaware Management Holdings Inc | 30.0K | 0.10% | 0.00% | Jun 2026 |
| Vanguard Global Advisers, LLC | 17.9K | 0.06% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 15.8K | 0.05% | -1.94% | Jun 2026 |
Lite Strategy, Inc. company profile
- Company name
- Lite Strategy, Inc.
- Ticker
- LITS.US
- Exchange
- USA Stocks
- Listed since
- Dec 18, 2003
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5
- Fiscal year end
- June
- Address
- 9920 Pacific Heights Blvd., San Diego, CA, United States, 92121
- Phone
- 858 369 7100
- Website
- litestrategy.com
About Lite Strategy, Inc.
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. It is also involved in holding Litecoin tokens as a primary reserve asset. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.
Lite Strategy, Inc. management
3- Mr. Justin J. File CPACEO, CFO, Corporate Secretary & Director · born 1970
- Ms. Anne FreseChief People Officer
- Dr. Robert D. Mass M.D.Strategic Advisor · born 1954